FibroGen, Inc (NASDAQ:FGEN) issued its earnings results on Monday. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by $0.01, Morningstar.com reports. FibroGen had a negative return on equity of 36.41% and a negative net margin of 37.60%. The company had revenue of $29 million during the quarter, compared to the consensus estimate of $34.80 million.

Shares of FibroGen (FGEN) traded up 48.20% during trading on Tuesday, hitting $49.50. The company had a trading volume of 6,692,389 shares. FibroGen has a 52 week low of $15.60 and a 52 week high of $51.45. The stock’s market capitalization is $3.46 billion. The firm’s 50 day moving average is $32.84 and its 200-day moving average is $27.51.

Several research firms have weighed in on FGEN. Citigroup Inc. raised their price target on FibroGen to $65.00 and gave the company a “top pick” rating in a report on Tuesday. BidaskClub cut FibroGen from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. William Blair reaffirmed an “outperform” rating on shares of FibroGen in a report on Monday, June 26th. Jefferies Group LLC began coverage on FibroGen in a report on Monday, July 10th. They issued a “buy” rating and a $50.00 price target on the stock. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $38.00 price target (up previously from $32.00) on shares of FibroGen in a report on Thursday, June 22nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. FibroGen has an average rating of “Buy” and a consensus target price of $56.86.

In related news, insider K Peony Yu sold 10,000 shares of the business’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $33.48, for a total value of $334,800.00. Following the sale, the insider now directly owns 226,507 shares in the company, valued at $7,583,454.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Pat Cotroneo sold 28,346 shares of the business’s stock in a transaction dated Wednesday, August 2nd. The stock was sold at an average price of $33.97, for a total value of $962,913.62. Following the completion of the sale, the vice president now owns 170,666 shares in the company, valued at $5,797,524.02. The disclosure for this sale can be found here. Insiders sold 409,974 shares of company stock worth $12,647,338 over the last quarter. 14.90% of the stock is owned by company insiders.

A number of large investors have recently modified their holdings of FGEN. Acadian Asset Management LLC increased its stake in shares of FibroGen by 1,455.0% in the first quarter. Acadian Asset Management LLC now owns 148,490 shares of the biopharmaceutical company’s stock worth $3,661,000 after buying an additional 138,941 shares during the period. Principal Financial Group Inc. increased its stake in shares of FibroGen by 0.4% in the first quarter. Principal Financial Group Inc. now owns 136,045 shares of the biopharmaceutical company’s stock worth $3,354,000 after buying an additional 504 shares during the period. Sphera Funds Management LTD. increased its stake in shares of FibroGen by 6.4% in the first quarter. Sphera Funds Management LTD. now owns 165,700 shares of the biopharmaceutical company’s stock worth $4,085,000 after buying an additional 10,000 shares during the period. Teachers Advisors LLC increased its stake in shares of FibroGen by 1.4% in the first quarter. Teachers Advisors LLC now owns 468,413 shares of the biopharmaceutical company’s stock worth $11,546,000 after buying an additional 6,512 shares during the period. Finally, Parametric Portfolio Associates LLC bought a new stake in shares of FibroGen during the first quarter worth about $249,000. Institutional investors and hedge funds own 43.45% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/08/fibrogen-inc-fgen-issues-quarterly-earnings-results.html.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Earnings History for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.